TP化疗方案联合曲妥珠单抗治疗HER2阳性乳腺癌的效果及对患者血清肿瘤标志物的影响
Effect of TP Chemotherapy Regimen Combined with Trastuzumab in the Treatment of HER2 Positive Breast Cancer and Its Influence on Serum Tumor Markers
严小杰1
作者信息
- 1. 274300 山东 菏泽,单县海吉亚医院肿瘤科
- 折叠
摘要
目的 探讨TP化疗方案联合曲妥珠单抗治疗HER2阳性乳腺癌的效果,以及对患者血清肿瘤标志物的影响.方法 选取2019年6月—2023年6月在单县海吉亚医院进行治疗的106例HER2阳性乳腺癌患者,所有患者按照治疗方案的不同分为给予TP化疗方案联合曲妥珠单抗治疗的联合组53例,以及采用TP化疗方案治疗的对照组53例.比较两组的疗效和治疗期间不良反应发生情况,以及治疗前后血清肿瘤标志物水平和生存质量.结果 治疗后两组血清肿瘤标志物中癌胚抗原、糖类抗原125和糖类抗原153水平均低于治疗前,且联合组低于对照组,差异有统计学意义(P＜0.05).治疗后两组生存质量乳腺癌功能评估测定量表评分均高于治疗前,且联合组高于对照组,差异有统计学意义(P＜0.05).联合组总有效率为45.28%、疾病控制率为81.13%,均高于对照组的20.75%和64.15%,差异有统计学意义(P＜0.05).两组不良反应发生率比较,差异无统计学意义(P＞0.05).结论 对于HER2阳性乳腺癌患者,采用TP化疗方案联合曲妥珠单抗治疗,较单独使用TP化疗方案具有更好的临床效果,能够进一步降低血清肿瘤标志物水平,且具有较好的安全性,值得临床推广使用.
Abstract
Objective To investigate the effect of TP chemotherapy regimen combined with trastuzumab in the treatment of HER2 positive breast cancer(BC),and the influence on serum tumor markers of patients.Methods A total of 106 HER2 positive BC patients who were treated in Hygeia Hospital of Shan County from June 2019 to June 2023 were selected.All patients were divided into the combined group of 53 patients who were treated with TP chemotherapy regimen combined with trastuzumab,and the control group of 53 patients who were treated with TP chemotherapy regimen alone.Compare the efficacy and incidence of adverse reactions during treatment between the two groups,as well as the levels of serum tumor markers and quality of life before and after treatment.Results After treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 125,and carbohydrate antigen 153 were significantly lower than before treatment in both groups,and the combined group was significantly lower than the control group(P<0.05).After treatment,the scores of the functional assessment of cancer therapy-breast cancer scale were significantly higher than those before treatment in both groups,and the scores in the combined group were significantly higher than those in the control group(P<0.05).The total effective rate and the disease control rate in the combined group was 45.28%and 81.13%,which were significantly higher than the control group's 20.75%and 64.15%respectively(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For HER2 positive BC patients,TP chemotherapy regimen combined with trastuzumab has better clinical effect than TP chemotherapy regimen alone,can further reduce the level of serum tumor markers,and has good safety,which is worthy of clinical promotion.
关键词
乳腺癌/HER2阳性/药物治疗/曲妥珠单抗/TP化疗方案/疗效/肿瘤标志物Key words
Breast Cancer/HER2/Medication/Trastuzumab/TP Chemotherapy Regimen/Curative Effect/Tumor Markers引用本文复制引用
出版年
2024
NETL
NSTL
万方数据